Mei-Zahav M, Orenti A, Jung A, Kerem E
ERJ Open Res. 2025; 11(1.
PMID: 39811546
PMC: 11726569.
DOI: 10.1183/23120541.00587-2024.
Zwitserloot A, Aziz S, Chen Y, Bannier M, Janssens H, Merkus P
Pediatr Pulmonol. 2025; 60(1):e27473.
PMID: 39785291
PMC: 11715133.
DOI: 10.1002/ppul.27473.
Dietz-Terjung S, Strassburg S, Schulte T, Dietz P, Weinreich G, Taube C
Diagnostics (Basel). 2025; 14(24.
PMID: 39767222
PMC: 11675557.
DOI: 10.3390/diagnostics14242859.
Pena-Rasgado C, Rodriguez-Manriquez E, Dundr M, Bridges R, Hastings M, Michaels W
NAR Mol Med. 2024; 1(4):ugae017.
PMID: 39582793
PMC: 11579696.
DOI: 10.1093/narmme/ugae017.
Sanders M, Beringer P
mSphere. 2024; 9(11):e0067124.
PMID: 39475317
PMC: 11580420.
DOI: 10.1128/msphere.00671-24.
Selective RNA pseudouridinylation in situ by circular gRNAs in designer organelles.
Schartel L, Jann C, Wierczeiko A, Butto T, Mundnich S, Marchand V
Nat Commun. 2024; 15(1):9177.
PMID: 39448590
PMC: 11502668.
DOI: 10.1038/s41467-024-53403-1.
Comparison of Reporting Quality in National Cystic Fibrosis Patient Registries: Implications for Identifying Use of Novel CFTR Modulators.
Tomlinson O, Mitchelmore P, Williams C
Pulm Ther. 2024; 10(4):427-438.
PMID: 39333383
PMC: 11574223.
DOI: 10.1007/s41030-024-00274-y.
Exploring Turkey's mosaic of novel variants and complex alleles in cystic fibrosis genetics.
Yildiz C, Selcuk Balci M, Karabulut S, Baser Z, Kalyoncu M, Metin Cakar N
Pediatr Pulmonol. 2024; 59(12):3540-3549.
PMID: 39291770
PMC: 11600995.
DOI: 10.1002/ppul.27249.
Beyond the 10%: Unraveling the genetic diversity in Turkish cystic fibrosis patients not eligible for CFTR modulators.
Yildiz C, Selcuk Balci M, Karabulut S, Baser Z, Yuksel Kalyoncu M, Metin Cakar N
Pediatr Pulmonol. 2024; 59(12):3250-3259.
PMID: 39031495
PMC: 11601005.
DOI: 10.1002/ppul.27181.
Molecular analysis of gene mutations among Iraqi cystic fibrosis patients.
Abdul-Qadir A, Al-Musawi B, Thejeal R, Al-Omar S
Egypt J Med Hum Genet. 2024; 22(1):45.
PMID: 38624701
PMC: 8110311.
DOI: 10.1186/s43042-021-00164-x.
Functional Consequences of CFTR Interactions in Cystic Fibrosis.
Ramananda Y, Naren A, Arora K
Int J Mol Sci. 2024; 25(6).
PMID: 38542363
PMC: 10970640.
DOI: 10.3390/ijms25063384.
In Silico and In Vitro Evaluation of the Mechanism of Action of Three VX809-Based Hybrid Derivatives as Correctors of the F508del CFTR Protein.
Baroni D, Scarano N, Ludovico A, Brandas C, Parodi A, Lunaccio D
Pharmaceuticals (Basel). 2023; 16(12).
PMID: 38139828
PMC: 10748060.
DOI: 10.3390/ph16121702.
Understanding CFTR Functionality: A Comprehensive Review of Tests and Modulator Therapy in Cystic Fibrosis.
Thakur S, Ankita , Dash S, Verma R, Kaur C, Kumar R
Cell Biochem Biophys. 2023; 82(1):15-34.
PMID: 38048024
DOI: 10.1007/s12013-023-01200-w.
Small-molecule correctors divert CFTR-F508del from ERAD by stabilizing sequential folding states.
Riepe C, Wachalska M, Deol K, Amaya A, Porteus M, Olzmann J
Mol Biol Cell. 2023; 35(2):ar15.
PMID: 38019608
PMC: 10881158.
DOI: 10.1091/mbc.E23-08-0336.
Clinical interpretation of cell-based non-invasive prenatal testing for monogenic disorders including repeat expansion disorders: potentials and pitfalls.
Jeppesen L, Hatt L, Singh R, Schelde P, Ravn K, Toft C
Front Genet. 2023; 14:1188472.
PMID: 37829280
PMC: 10565008.
DOI: 10.3389/fgene.2023.1188472.
Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2.
Bongiorno R, Ludovico A, Moran O, Baroni D
Int J Mol Sci. 2023; 24(16).
PMID: 37629017
PMC: 10454486.
DOI: 10.3390/ijms241612838.
Druggable redox pathways against Mycobacterium abscessus in cystic fibrosis patient-derived airway organoids.
Leon-Icaza S, Bagayoko S, Verge R, Iakobachvili N, Ferrand C, Aydogan T
PLoS Pathog. 2023; 19(8):e1011559.
PMID: 37619220
PMC: 10449475.
DOI: 10.1371/journal.ppat.1011559.
Risk factors for forced expiratory volume in 1 s decline in European patients with cystic fibrosis: data from the European Cystic Fibrosis Society Patient Registry.
Hatziagorou E, Fieuws S, Orenti A, Naehrlich L, Krivec U, Mei-Zahav M
ERJ Open Res. 2023; 9(3).
PMID: 37483280
PMC: 10359040.
DOI: 10.1183/23120541.00449-2022.
Site-Specific RNA Editing of Stop Mutations in the CFTR mRNA of Human Bronchial Cultured Cells.
Chiavetta R, Titoli S, Barra V, Cancemi P, Melfi R, Di Leonardo A
Int J Mol Sci. 2023; 24(13).
PMID: 37446121
PMC: 10342162.
DOI: 10.3390/ijms241310940.
Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease.
Giallongo A, Parisi G, Papale M, Manti S, Mule E, Aloisio D
Genes (Basel). 2023; 14(2).
PMID: 36833376
PMC: 9956139.
DOI: 10.3390/genes14020449.